πŸ‡ΊπŸ‡Έ FDA
Patent

US 12312391

Anti-mutated KRAS T cell receptors

granted A61KA61K2239/38A61K2239/54

Quick answer

US patent 12312391 (Anti-mutated KRAS T cell receptors) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2239/38, A61K2239/54, A61K38/00, A61K39/001164